BACKGROUND: Sofosbuvir is a chain-terminating nucleotide analogue inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase that is efficacious in subjects with HCV genotype 1-6 infection. Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B. METHODS: NS5B sequencing and susceptibility testing of HCV from subjects infected with genotypes 1-6 who participated in phase 2 and 3 sofosbuvir clinical trials was performed. RESULTS: No NS5B variants present at baseline among 1645 sofosbuvir-treated subjects were associated with treatment failure; sofosbuvir susceptibility was within 2-fold of reference. Among 282 subjects who did not achieve sustained virologic response, no novel sofosbuvir resistance-associated variants were identified, and the NS5B changes observed did not confer significant reductions in sofosbuvir susceptibility. In 1 subject with S282T observed at relapse 4 weeks after sofosbuvir monotherapy, the resistant variant (13.5-fold reduced sofosbuvir susceptibility, replication capacity <2% of control) became undetectable by deep sequencing 12 weeks after treatment. L159F and V321A were identified as treatment-emergent variants but did not confer resistance to sofosbuvir in the replicon system. CONCLUSIONS: These data demonstrate a uniform susceptibility of subject-derived HCV to sofosbuvir, and also show that selection of sofosbuvir-resistant HCV is exceedingly rare and is associated with a significant reduction in viral fitness.
BACKGROUND:Sofosbuvir is a chain-terminating nucleotide analogue inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase that is efficacious in subjects with HCV genotype 1-6 infection. Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B. METHODS: NS5B sequencing and susceptibility testing of HCV from subjects infected with genotypes 1-6 who participated in phase 2 and 3 sofosbuvir clinical trials was performed. RESULTS: No NS5B variants present at baseline among 1645 sofosbuvir-treated subjects were associated with treatment failure; sofosbuvir susceptibility was within 2-fold of reference. Among 282 subjects who did not achieve sustained virologic response, no novel sofosbuvir resistance-associated variants were identified, and the NS5B changes observed did not confer significant reductions in sofosbuvir susceptibility. In 1 subject with S282T observed at relapse 4 weeks after sofosbuvir monotherapy, the resistant variant (13.5-fold reduced sofosbuvir susceptibility, replication capacity <2% of control) became undetectable by deep sequencing 12 weeks after treatment. L159F and V321A were identified as treatment-emergent variants but did not confer resistance to sofosbuvir in the replicon system. CONCLUSIONS: These data demonstrate a uniform susceptibility of subject-derived HCV to sofosbuvir, and also show that selection of sofosbuvir-resistant HCV is exceedingly rare and is associated with a significant reduction in viral fitness.
Authors: Lieven J Stuyver; Tamara R McBrayer; Phillip M Tharnish; Jeremy Clark; Laurent Hollecker; Stefania Lostia; Tammy Nachman; Jason Grier; Matthew A Bennett; Meng-Yu Xie; Raymond F Schinazi; John D Morrey; Justin L Julander; Phillip A Furman; Michael J Otto Journal: Antivir Chem Chemother Date: 2006
Authors: John G McHutchison; Michael P Manns; Andrew J Muir; Norah A Terrault; Ira M Jacobson; Nezam H Afdhal; E Jenny Heathcote; Stefan Zeuzem; Hendrik W Reesink; Jyotsna Garg; Mohammad Bsharat; Shelley George; Robert S Kauffman; Nathalie Adda; Adrian M Di Bisceglie Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Andrew Bae; Siu-Chi Sun; Xiaoping Qi; Xiaowu Chen; Karin Ku; Angela Worth; Kelly A Wong; Jeanette Harris; Michael D Miller; Hongmei Mo Journal: Antimicrob Agents Chemother Date: 2010-09-20 Impact factor: 5.191
Authors: Sophie Le Pogam; Wen-Rong Jiang; Vincent Leveque; Sonal Rajyaguru; Han Ma; Hyunsoon Kang; Sharon Jiang; Margaret Singer; Samir Ali; Klaus Klumpp; Dave Smith; Julian Symons; Nick Cammack; Isabel Nájera Journal: Virology Date: 2006-05-19 Impact factor: 3.616
Authors: Giovanni Migliaccio; Joanne E Tomassini; Steven S Carroll; Licia Tomei; Sergio Altamura; Balkrishen Bhat; Linda Bartholomew; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; Riccardo Cortese; Raffaele De Francesco; Anne B Eldrup; Krista L Getty; Xiaoli S Hou; Robert L LaFemina; Steven W Ludmerer; Malcolm MacCoss; Daniel R McMasters; Mark W Stahlhut; David B Olsen; Daria J Hazuda; Osvaldo A Flores Journal: J Biol Chem Date: 2003-09-08 Impact factor: 5.157
Authors: Chih-Ming Chen; Yupeng He; Liangjun Lu; Hock Ben Lim; Rakesh L Tripathi; Tim Middleton; Lisa E Hernandez; David W A Beno; Michelle A Long; Warren M Kati; Todd D Bosse; Daniel P Larson; Rolf Wagner; Robert E Lanford; William E Kohlbrenner; Dale J Kempf; Tami J Pilot-Matias; Akhteruzzaman Molla Journal: Antimicrob Agents Chemother Date: 2007-10-01 Impact factor: 5.191
Authors: Steven W Ludmerer; Donald J Graham; Evelyn Boots; Edward M Murray; Amy Simcoe; Eric J Markel; Jay A Grobler; Osvaldo A Flores; David B Olsen; Daria J Hazuda; Robert L LaFemina Journal: Antimicrob Agents Chemother Date: 2005-05 Impact factor: 5.191
Authors: Holly Freedman; Juthika Kundu; Egor Petrovitch Tchesnokov; John Lok Man Law; James A Nieman; Raymond F Schinazi; D Lorne Tyrrell; Matthias Gotte; Michael Houghton Journal: J Chem Inf Model Date: 2020-12-01 Impact factor: 4.956
Authors: Karin S Ku; Ramakrishna K Chodavarapu; Ross Martin; Michael D Miller; Hongmei Mo; Evguenia S Svarovskaia Journal: J Clin Microbiol Date: 2016-05-04 Impact factor: 5.948
Authors: Evguenia S Svarovskaia; Edward Gane; Hadas Dvory-Sobol; Ross Martin; Brian Doehle; Charlotte Hedskog; Ira M Jacobson; David R Nelson; Eric Lawitz; Diana M Brainard; John G McHutchison; Michael D Miller; Hongmei Mo Journal: J Infect Dis Date: 2015-11-24 Impact factor: 5.226